Who are the members in SENATOR?

- Prof. Denis O’Mahony, University College Cork (UCC), Cork, Ireland
- Prof. Dr. Mirko Petrovic, Universitair Ziekenhuis Gent (UGENT), Ghent, Belgium
- Joseph McMullin, ClanWilliam Health Limited (ClanWilliam), Dublin, Ireland
- Dr. Alfonso Cruz-Jentoft, Hospital Universitario Ramón y Cajal (SERMAS), Madrid, Spain
- Prof. Dr. Antonio Cherubini, Istituto Nazionale di Riposo e Cura per Anziani (INRCA) – Istituto di Ricovery e Cura a Carattere Scientifico (IRCCS), Ancona, Italy
- Prof. Dr. Ric Fordham, University of East Anglia (UEA), Norwich Medical School, Norwich, UK
- Dr. Adalsteinn Gudmundsson, Landspitali Háskólasjúkrahúsp (LUH), Reykjavik, Iceland
- Dr. Philippe Foerster, ClinInfo S.A. (ClinInfo), Lyon, France
- Dr. Roy Soiza, Grampian Health Board (NIHSG), Aberdeen, UK
- Dr. Otilia Postea, ARTTIC (ART), Munich, Germany

Who are the key contacts in SENATOR?

Coordinator: University College Cork, Prof. Denis O’Mahony
Project Manager: ARTTIC, Munich Dr. Otilia Postea
Project website address: www.senator-project.eu

SENATOR

Development and clinical trials of a new Software ENgine for the Assessment & optimization of drug and non-drug Therapy in Older peRsOns

SENATOR is a medium-scale collaborative project that has received funding from the European Commission Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 305930.
Why SENATOR?

The number of older people with multi-morbidity in Europe is growing steadily. The increasing number of multi-morbid people is strongly linked to adverse consequences of polypharmacy, inappropriate prescribing and excessive health care costs. In tandem with drug therapy problems, there is underuse of non-drug therapies in the treatment of chronic diseases.

What is SENATOR?

The SENATOR project brings together renowned researchers from across Europe, with a strong scientific and clinical background in Geriatric Medicine, Geriatric Pharmacotherapy, biomedical statistics, clinical pharmacy, medical software development, pharmaeconomics, pharmaco-epidemiology and clinical trial management. The aim is to develop and test a highly-powered and efficient software engine (SENATOR) for screening the clinical status and optimizing pharmacological and non-pharmacological therapy of older people with multi-morbidity who are hospitalized with acute illness.

SENATOR consists of 12 work packages that range from design and validation of a novel ADR risk assessment tool, to creation of a compendium of non-drug therapies for the management of common geriatric syndromes, to SENATOR software engine design and validation, to randomized controlled clinical trial testing of SENATOR software as a novel intervention for optimization of drug therapy in older hospitalized people, to economic assessment of the possible benefit of the SENATOR software intervention in the hospital setting.

These work packages are spread over a 5 year interval and will attempt to provide practical clinical solutions to the increasing challenge of optimizing drug and non-drug therapy in older people with multi-morbid illness, whilst simultaneously minimizing excess expenditure on pharmacotherapy in this rapidly growing patient population.

SENATOR software will be tested in a controlled clinical trial to determine if it has the capability of reducing non-trivial adverse drug reactions and cost of care in older people in hospital with unselected acute illness. This trial will involve approximately 1800 patients recruited in the six participating clinical centres over a 3 year period.

What will be the impact of SENATOR?

The SENATOR project aims are:
- To deliver treatments that are better suited to the needs of older people
- To lower healthcare costs while maintaining high-quality care
- To embark on standard setting in geriatric medicine

Key Data

- Start date: 1st October 2012
- Runtime: 5 years
- Structure: 12 Work packages
- Budget: € 7,810,965
- EC Funding: € 5,938,947

Who supports SENATOR?

SENATOR is a medium-scale collaborative project that has received funding from the European Commission Seventh Framework Programme [FP7/2007-2013] under grant agreement n° 305930.